請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28323完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王水深(Shoei-Shen Wang) | |
| dc.contributor.author | Shao-Jung Li | en |
| dc.contributor.author | 李紹榕 | zh_TW |
| dc.date.accessioned | 2021-06-13T00:05:11Z | - |
| dc.date.available | 2007-08-08 | |
| dc.date.copyright | 2007-08-08 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-28 | |
| dc.identifier.citation | 1.(1980). 'Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study.' Eur J Respir Dis Suppl 111: 93-108.
2.Abel, R. M., M. J. Buckley, et al. (1976). 'Etiology, incidence, and prognosis of renal failure following cardiac operations. Results of a prospective analysis of 500 consecutive patients.' J Thorac Cardiovasc Surg 71(3): 323-33. 3.Acchiardo, S., A. P. Kraus, Jr., et al. (1989). 'Beta 2-microglobulin levels in patients with renal insufficiency.' Am J Kidney Dis 13(1): 70-4. 4.Ahlstrom, A., M. Tallgren, et al. (2004). 'Evolution and predictive power of serum cystatin C in acute renal failure.' Clin Nephrol 62(5): 344-50. 5.Arstall, M. A., J. Yang, et al. (1995). 'N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects.' Circulation 92(10): 2855-62. 6.Aruoma, O. I., B. Halliwell, et al. (1989). 'The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.' Free Radic Biol Med 6(6): 593-7. 7.Ascione, R., C. T. Lloyd, et al. (2000). 'Inflammatory response after coronary revascularization with or without cardiopulmonary bypass.' Ann Thorac Surg 69(4): 1198-204. 8.Bagshaw, S. M., F. A. McAlister, et al. (2006). 'Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence.' Arch Intern Med 166(2): 161-6. 9.Baier, J. E., H. A. Neumann, et al. (1996). '[Radiation protection through cytokine release by N-acetylcysteine].' Strahlenther Onkol 172(2): 91-8. 10.Berggard, I. and A. G. Bearn (1968). 'Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids.' J Biol Chem 243(15): 4095-103. 11.Boesgaard, S., J. Aldershvile, et al. (1991). 'Continuous oral N-acetylcysteine treatment and development of nitrate tolerance in patients with stable angina pectoris.' J Cardiovasc Pharmacol 17(6): 889-93. 12.Borgstrom, L., B. Kagedal, et al. (1986). 'Pharmacokinetics of N-acetylcysteine in man.' Eur J Clin Pharmacol 31(2): 217-22. 13.Burns, K. E., M. W. Chu, et al. (2005). 'Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial.' Jama 294(3): 342-50. 14.Ceconi, C., S. Curello, et al. (1988). 'The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetyl cysteine.' J Mol Cell Cardiol 20(1): 5-13. 15.Chertow, G. M., J. M. Lazarus, et al. (1997). 'Preoperative renal risk stratification.' Circulation 95(4): 878-84. 16.Coll, E., A. Botey, et al. (2000). 'Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment.' Am J Kidney Dis 36(1): 29-34. 17.Conlon, P. J., M. Stafford-Smith, et al. (1999). 'Acute renal failure following cardiac surgery.' Nephrol Dial Transplant 14(5): 1158-62. 18.Dharnidharka, V. R., C. Kwon, et al. (2002). 'Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.' Am J Kidney Dis 40(2): 221-6. 19.DiMari, J., J. Megyesi, et al. (1997). 'N-acetyl cysteine ameliorates ischemic renal failure.' Am J Physiol 272(3 Pt 2): F292-8. 20.Downing, S. W. and L. H. Edmunds, Jr. (1992). 'Release of vasoactive substances during cardiopulmonary bypass.' Ann Thorac Surg 54(6): 1236-43. 21.El-Hamamsy, I., L. M. Stevens, et al. (2007). 'Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.' J Thorac Cardiovasc Surg 133(1): 7-12. 22.Erlandsen, E. J., E. Randers, et al. (1999). 'Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System.' Scand J Clin Lab Invest 59(1): 1-8. 23.Finney, H., D. J. Newman, et al. (2000). 'Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance.' Ann Clin Biochem 37 ( Pt 1): 49-59. 24.Fischer, U. M., P. Tossios, et al. (2005). 'Renal protection by radical scavenging in cardiac surgery patients.' Curr Med Res Opin 21(8): 1161-4. 25.Fliser, D. and E. Ritz (2001). 'Serum cystatin C concentration as a marker of renal dysfunction in the elderly.' Am J Kidney Dis 37(1): 79-83. 26.Fransen, E., J. Maessen, et al. (1998). 'Systemic inflammation present in patients undergoing CABG without extracorporeal circulation.' Chest 113(5): 1290-5. 27.Gokkusu, C. A., T. A. Ozden, et al. (2004). 'Relationship between plasma Cystatin C and creatinine in chronic renal diseases and Tx-transplant patients.' Clin Biochem 37(2): 94-7. 28.Gormley, S. M., W. T. McBride, et al. (2000). 'Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery.' Anesthesiology 93(5): 1210-6; discussion 5A. 29.Haase, M., A. Haase-Fielitz, et al. (2007). 'Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients.' Crit Care Med 35(5): 1324-31. 30.Hansen, P. R. (1991). 'Lipoprotein(a) reduction by N-acetylcysteine.' Lancet 337(8742): 672-3. 31.Herget-Rosenthal, S., G. Marggraf, et al. (2004). 'Early detection of acute renal failure by serum cystatin C.' Kidney Int 66(3): 1115-22. 32.Holzheimer, R. G., R. G. Molloy, et al. (1994). 'IL-6 and TNF alpha release in association with neutrophil activation after cardiopulmonary bypass surgery.' Infection 22(1): 37-42. 33.Hynninen, M. S., T. T. Niemi, et al. (2006). 'N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial.' Anesth Analg 102(6): 1638-45. 34.Ichihara, T., K. Yasuura, et al. (1994). 'The effects of using a leukocyte removal filter during cold blood cardioplegia.' Surg Today 24(11): 966-72. 35.Kalfin, R. E., R. M. Engelman, et al. (1993). 'Induction of interleukin-8 expression during cardiopulmonary bypass.' Circulation 88(5 Pt 2): II401-6. 36.Khachigian, L. M., T. Collins, et al. (1997). 'N-acetyl cysteine blocks mesangial VCAM-1 and NF-kappa B expression in vivo.' Am J Pathol 151(5): 1225-9. 37.Kirklin, J. K., D. E. Chenoweth, et al. (1986). 'Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state.' Ann Thorac Surg 41(2): 193-9. 38.Kleinveld, H. A., P. N. Demacker, et al. (1992). 'Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects.' Eur J Clin Pharmacol 43(6): 639-42. 39.Knight, E. L., J. C. Verhave, et al. (2004). 'Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.' Kidney Int 65(4): 1416-21. 40.Lassnigg, A., D. Schmidlin, et al. (2004). 'Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study.' J Am Soc Nephrol 15(6): 1597-605. 41.Liu, J., G. K. Sukhova, et al. (2004). 'Lysosomal cysteine proteases in atherosclerosis.' Arterioscler Thromb Vasc Biol 24(8): 1359-66. 42.Magder, S. (2006). 'Reactive oxygen species: toxic molecules or spark of life?' Crit Care 10(1): 208. 43.Mangano, C. M., L. S. Diamondstone, et al. (1998). 'Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group.' Ann Intern Med 128(3): 194-203. 44.Mares, J., D. Stejskal, et al. (2003). 'Use of cystatin C determination in clinical diagnostics.' Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147(2): 177-80. 45.Meldrum, D. R. and K. K. Donnahoo (1999). 'Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome.' J Surg Res 85(2): 185-99. 46.Morgan, L. R., M. R. Holdiness, et al. (1983). 'N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.' Semin Oncol 10(1 Suppl 1): 56-61. 47.Murkin, J. M., J. S. Martzke, et al. (1995). 'A randomized study of the influence of perfusion technique and pH management strategy in 316 patients undergoing coronary artery bypass surgery. II. Neurologic and cognitive outcomes.' J Thorac Cardiovasc Surg 110(2): 349-62. 48.Nakamuro, K., N. Tanigaki, et al. (1973). 'Multiple common properties of human beta2-microglobulin and the common portion fragment derived from HL-A antigen molecules.' Proc Natl Acad Sci U S A 70(10): 2863-5. 49.Newman, D. J., H. Thakkar, et al. (1995). 'Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine.' Kidney Int 47(1): 312-8. 50.Ortolani, O., A. Conti, et al. (2000). 'Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome.' Shock 13(1): 14-8. 51.Patel, R. L., M. R. Turtle, et al. (1996). 'Alpha-stat acid-base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting.' J Thorac Cardiovasc Surg 111(6): 1267-79. 52.Pollman, M. J., J. L. Hall, et al. (1999). 'Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype.' Circ Res 84(1): 113-21. 53.Prescott, L. F., J. Park, et al. (1977). 'Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine.' Lancet 2(8035): 432-4. 54.Rinder, C. S., M. Fontes, et al. (2003). 'Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury.' Ann Thorac Surg 75(3): 899-905. 55.Ristikankare, A., T. Kuitunen, et al. (2006). 'Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery.' Br J Anaesth 97(5): 611-6. 56.Robicsek F, M. T., Niesluchowski W, et al (1983). Vasomotor activity during cardiopulmonary bypass, in Utley JR (ed). Pathophysiology and Techniques of Cardiopulmonary Bypass. Baltimore, Williams & Wilkins. II: 1. 57.Safirstein, R., L. Andrade, et al. (2000). 'Acetylcysteine and nephrotoxic effects of radiographic contrast agents--a new use for an old drug.' N Engl J Med 343(3): 210-2. 58.Salom, M. G., P. Ramirez, et al. (1998). 'Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion.' Transplantation 65(10): 1315-21. 59.Scaduto, R. C., Jr., V. H. Gattone, 2nd, et al. (1991). 'Elevation of renal glutathione enhances ischemic injury.' Ren Physiol Biochem 14(6): 259-70. 60.Sehirli, A. O., G. Sener, et al. (2003). 'Protective effect of N-acetylcysteine on renal ischemia/reperfusion injury in the rat.' J Nephrol 16(1): 75-80. 61.Sen, C. K., T. Rankinen, et al. (1994). 'Oxidative stress after human exercise: effect of N-acetylcysteine supplementation.' J Appl Physiol 76(6): 2570-7. 62.Shalansky, S. J., G. E. Pate, et al. (2005). 'N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration.' Heart 91(8): 997-9. 63.Sochman, J. (2002). 'N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?!' J Am Coll Cardiol 39(9): 1422-8. 64.Sucu, N., I. Cinel, et al. (2004). 'N-acetylcysteine for preventing pump-induced oxidoinflammatory response during cardiopulmonary bypass.' Surg Today 34(3): 237-42. 65.Tang, L. D., J. Z. Sun, et al. (1991). 'Beneficial effects of N-acetylcysteine and cysteine in stunned myocardium in perfused rat heart.' Br J Pharmacol 102(3): 601-6. 66.Tepel, M., M. van der Giet, et al. (2000). 'Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.' N Engl J Med 343(3): 180-4. 67.Trollfors, B. and R. Norrby (1981). 'Estimation of glomerular filtration rate by serum creatinine and serum beta 2-microglobulin.' Nephron 28(4): 196-9. 68.Verhave, J. C., R. T. Gansevoort, et al. (2004). 'An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population.' Kidney Int Suppl(92): S18-21. 69.Wagner, P. D., O. Mathieu-Costello, et al. (1989). 'Protection against pulmonary O2 toxicity by N-acetylcysteine.' Eur Respir J 2(2): 116-26. 70.Wasen, E., R. Isoaho, et al. (2003). 'Serum cystatin C in the aged: relationships with health status.' Am J Kidney Dis 42(1): 36-43. 71.Westhuyzen, J., Z. H. Endre, et al. (2003). 'Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit.' Nephrol Dial Transplant 18(3): 543-51. 72.Wibell, L., P. E. Evrin, et al. (1973). 'Serum 2 -microglobulin in renal disease.' Nephron 10(5): 320-31. 73.Witko-Sarsat, V., V. Gausson, et al. (2003). 'AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients.' Kidney Int 64(1): 82-91. 74.Zanardo, G., P. Michielon, et al. (1994). 'Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors.' J Thorac Cardiovasc Surg 107(6): 1489-95. 75.Zhang, H., H. Spapen, et al. (1995). 'Effects of N-acetyl-L-cysteine on regional blood flow during endotoxic shock.' Eur Surg Res 27(5): 292-300. 76.Zhu, J., R. Yin, et al. (2007). 'N-acetylcysteine to ameliorate acute renal injury in a rat cardiopulmonary bypass model.' J Thorac Cardiovasc Surg 133(3): 696-703. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28323 | - |
| dc.description.abstract | 背景
病人接受心臟血管手術，在進行體外循環﹙cardiopulmonary bypass, CPB﹚的過程中，會經歷體內發炎反應遽增及血液循環改變；因此而導致的急性腎功能損傷，常常會延長病人的住院天數及增加醫療費用，甚至造成死亡率增加，尤其是對原先腎功能不全的病人影響更鉅。近來愈來愈多的國外學術研究指出，乙醯半胱胺酸（N-Acetylcysteine，NAC）可以降低顯影劑所引起的腎毒性，但是它對體外循環後的急性腎衰竭鮮少有相關的研究報告。 材料與方法 1. 凡在亞東醫院接受需體外循環之心臟血管手術病患即為本次研究的主要對象。實驗方法採隨機，雙盲，前瞻性設計，隨機決定接受NAC或安慰劑(Placebo，不含有效成分NAC之同劑型產品)。術前請病患簽署受試者同意書，並需記錄病人個人資料；在病患接受手術前一天開始由負責藥師隨機給予口服研究藥品，病患及醫師皆不知道服藥的種類；同時，在手術前12小時開始給予0.45% saline。在資料收集後，評估病患服用NAC對於體外循環誘發之腎衰竭的預防療效。根據病患接受手術前的腎功能(尿素氮/血清肌胺酸酐值，BUN/creatinine)為基準值，如果在接受手術後48小時內血清肌胺酸酐值（serum creatinine，Scr）增加0.5mg/dl或是上升25%以上，就視為體外循環造成的急性腎功能損傷。 研究對象排除條款： 洗腎病患（Dialyzed patients） 急性腎衰竭（Acute renal failure） 左心室射出率（left ventricular ejection fraction, LVEF）≦30%. 慢性阻塞性肺疾病急性發作或氣喘惡化（Acute exacerbation of chronic obstructive lung disease or asthma exacerbation） NAC過敏 2. 樣本數：60名 3. 研究方法： i. 收集個案的基本資料、手術過程、術後恢復期。需記錄病人姓名、年齡、性別、身高、體重、診斷、手術名稱、病史(高血壓、糖尿病、心臟衰竭、末梢血管疾病)、手術前12小時的BUN/Scr、手術前24小時內曾經使用的藥物(mannitol、diuretics、ACE-I、CCB、dopamine、theophylline...等會影響腎臟功能的藥物)。 ii. 資料收集：在病人被手術前12小時、手術當天、手術後48小時及第5天，抽血評估病人腎功能狀況。術前及術後24小時之cystatin C（Cys C）及β2 Microglobulin﹙β2m﹚也一起測量。 結果 總計有55位病患接受雙盲隨機分組試驗，29位接受NAC治療，26位接受Placebo；排除LVEF<30%的病患後，NAC治療組有28位，Placebo組有23位。單變數分析發現年齡、冠狀動脈繞道手術加上瓣膜手術、術前12小時BUN落在3rd tertile者、手術當天BUN及creatinine clearance、術前β2m及Cys C這幾個因子是有意義的。多變數分析僅有冠狀動脈繞道手術加上瓣膜手術有統計學上之趨勢，但未達統計學上有意義之程度(OR = 8.49; 95% CI: 0.82, 88.38, P value = 0.07) 。 若考慮樣本數過小之因素，另加計72位同時期未用藥之病患資料；這些人經比對Placebo組後因無統計學上之差異，加入Placebo組併計。去除其中LVEF<30%的病患之後計有89位Placebo組。所以第二個分析總計包括117位病患，當成cohort study，雖然統計上之效力可能會降低，不若雙盲隨機化、安慰劑控制之臨床試驗結果。兩組基本資料之描述性統計，並無統計學上之差異。單變數分析之結果，令人驚訝的是NAC治療會增加急性腎衰竭風險達2.62倍多(95% CI: 1.10, 6.27)。冠狀動脈繞道手術加上瓣膜手術相對於單做瓣膜手術者也有顯著風險達5.42倍多(95% CI: 2.16, 13.58)。糖尿病及高血壓也明顯增加急性腎臟傷害發生率。較高的術前12小時BUN，手術當天BUN、Creatinine、Creatinine clearance，及術前β2m高低也會增加風險。雖然沒有統計學上之意義，Reopen after surgery也會增加風險達3倍多。 在控制干擾因子之後，由多變數分析可看出NAC的relative risk (OR)為2.54 (95% CI: 0.82, 7.88; relative to placebo group)，雖然沒有統計學上之意義。此外，僅有冠狀動脈繞道手術加上瓣膜手術(OR = 4.02; 95% CI: 1.19, 13.64, 相對於單做瓣膜手術者)，術前β2m落在3rd tertile者(OR = 5.63; 95% CI: 1.01, 31.20, relative to the 1st tertile) 在兩組間有統計學上之意義。 結論 我們的數據與期望的結果顯示十分不同。由兩種分析看來，冠狀動脈繞道手術加上瓣膜手術、術前β2m落在3rd tertile者與結果有重要的相互關聯。但是在術前以抗氧化劑NAC處理者，當與安慰劑組相比較時反而會增加急性腎衰竭的危險；或許因為NAC保護腎的機制不同於CPB 引起的損害路徑，或不足以減少CPB 引起的損害。因為研究沒擁有足夠大的樣本數來反映出顯著的統計意義，無法斷言NAC對CPB 引起的腎的傷害保護的影響，但其趨勢值得未來做更多的研究。 | zh_TW |
| dc.description.abstract | Background
Reactive oxygen species have been shown to cause contrast-induced nephrotoxicity (CIN). According to the previous studies, the N-acetylcysteine (NAC) has been proved to be advantageous in the avoidance of CIN. We developed this study to evaluate the efficacy of the antioxidant NAC in limiting the renal injury after the cardiovascular surgery with cardiopulmonary bypass (CPB). Materials and methods All patients who would receive a cardiac surgery with cardiopulmonary bypass were included in this study. The patients were randomly assigned to receive either NAC (600 mg orally twice daily for 4 doses) with 0.45% saline intravenously, before and after cardiopulmonary bypass, or placebo with 0.45% saline. Serum creatinine and blood urea nitrogen were measured before, 48 h and 5 days after the operation procedure. Besides, cystatin C (Cys C) and β2-microglobulin (β2m) were measured just before and after the operation procedure. Results A total of 55 patients were recruited in this randomized clinical trial. Among them, 29 subjects were randomly assigned to the intervention group of NAC. After excluding the cases with left ventricular ejection fraction（LVEF）less than 30%, there were 28 subjects in the experiment group with intervention and 23 in the control group (placebo). No particular difference was found in the baseline comparison results. In univariate analyses, elevated risks of acute renal insult were detected for age, CABG plus valve procedure, 3rd tertile of BUN level (12 hours before surgery), BUN and creatinine clearance levels on surgery day, β2m and Cys C levels right before surgery. Unfortunately, only a borderline significance was identified for the procedure of CABG plus valve (OR = 8.49; 95% CI: 0.82, 88.38, p value = 0.07) in multivariate analysis. Because of small sample size and difficulty on statistical analysis, we recruited another cohort into placebo control group for further analysis. A total of 117 patients were recruited in the further analysis. No any significantly statistical difference was detected in the baseline comparisons before intervention. In univariate analysis, amazingly, NAC treatment before surgery increased the risk of acute renal insult by 2.62 folds (95% CI: 1.10, 6.27). Subjects who underwent CABG plus valve procedure had a remarkable OR of 5.42 (95% CI: 2.16, 13.58), relative to the ones with valve procedure only. Also, patients with diabetes and hypertension had significantly elevated risk of outcome incidence. Meanwhile, higher BUN level 12 hours before surgery, BUN, serum creatinine, creatinine clearance levels on the surgery day, andβ2m level right before surgery showed remarkably altered risk of acute renal insult. Although not significant, reopen after surgery might dramatically raise the risk of outcome by approximate three folds. In multivariate analysis, the relative risk (OR) of NAC, after controlling confounders, was 2.54 folds (95% CI: 0.82, 7.88; relative to placebo group) without statistical significance. Besides, only the significance of CABG plus valve procedure, (OR = 4.02; 95% CI: 1.19, 13.64, relative to the ones with mere valve procedure), and 3rd tertile of β2m level before surgery (OR = 5.63; 95% CI: 1.01, 31.20, relative to the 1st tertile) remained significant. Conclusion NAC cannot protect the renal damage during CPB. CABG plus valve procedure and higher β2m level before surgery (2.83~41.05, upper limit of normal is 2.4 mg/L for both, males and females) are 2 independent risk factor for risk of renal injury. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T00:05:11Z (GMT). No. of bitstreams: 1 ntu-96-P92421018-1.pdf: 479875 bytes, checksum: e2afa8bad160666c2a58fcdf53628deb (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 口試委員會審定書 …………………………………………………… i
致謝 …………………………………………………………………… ii 中文摘要 ……………………………………………………………… iii 英文摘要 ……………………………………………………………… vi 第一章 緒論 …………………………………………………………… 1 第二章 材料與方法 …………………………………………………… 9 第三章 結果 ……………………………………………………………12 第四章 討論 ……………………………………………………………14 第五章 結論與展望 ……………………………………………………20 第六章 參考文獻 ………………………………………………………22 第七章 表 ………………………………………………………………33 附錄一：EuroScore ……………………………………………………47 附錄二：縮寫名詞總覽…………………………………………………48 | |
| dc.language.iso | zh-TW | |
| dc.subject | 雙盲隨機試驗 | zh_TW |
| dc.subject | 血清肌胺酸酐 | zh_TW |
| dc.subject | 體外循環 | zh_TW |
| dc.subject | 乙醯半胱胺酸 | zh_TW |
| dc.subject | 急性腎傷害 | zh_TW |
| dc.subject | N-acetylcysteine | en |
| dc.subject | β2-microglobulin | en |
| dc.subject | renal injury | en |
| dc.subject | cardiopulmonary bypass | en |
| dc.subject | randomized clinical trial | en |
| dc.subject | cystatin C | en |
| dc.title | 乙醯半胱胺酸在接受體外循環的病人對急性腎傷害的保護效果 | zh_TW |
| dc.title | Effect of N-Acetylcysteine in protecting against acute renal insult in patients undergoing cardiopulmonary bypass | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李源德(Yuan-The Lee),高嘉宏(Jia-Horng Kao) | |
| dc.subject.keyword | 體外循環,乙醯半胱胺酸,急性腎傷害,雙盲隨機試驗,血清肌胺酸酐, | zh_TW |
| dc.subject.keyword | N-acetylcysteine,cardiopulmonary bypass,renal injury,randomized clinical trial,cystatin C,β2-microglobulin, | en |
| dc.relation.page | 48 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-30 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 468.63 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。